[HTML][HTML] Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects

S Mirzaei, MH Gholami, F Hashemi, A Zabolian… - Drug Discovery …, 2022 - Elsevier
Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Composition design and medical application of liposomes

M Li, C Du, N Guo, Y Teng, X Meng, H Sun, S Li… - European journal of …, 2019 - Elsevier
Liposomes, which possess the properties of nano-scale, biofilm similar structure, excellent
biocompatibility, become more and more useful in the drug development as the delivery …

Challenges for assessing replicability in preclinical cancer biology

TM Errington, A Denis, N Perfito, E Iorns, BA Nosek - elife, 2021 - elifesciences.org
We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of
preclinical research in cancer biology. The initial aim of the project was to repeat 193 …

[HTML][HTML] Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids

B Schuster, M Junkin, SS Kashaf… - Nature …, 2020 - nature.com
Abstract Three-dimensional (3D) cell culture technologies, such as organoids, are
physiologically relevant models for basic and clinical applications. Automated microfluidics …

Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and …

J Fu, T Li, Y Yang, L Jiang, W Wang, L Fu, Y Zhu… - Biomaterials, 2021 - Elsevier
Hypoxia has been firmly correlated to the drug resistance of solid tumors. Alleviation of
hypoxia by tumor reoxygenation is expected to sensitize the chemotherapy toward solid …

[PDF][PDF] Systems biology of cancer metastasis

Y Suhail, MP Cain, K Vanaja, PA Kurywchak… - Cell systems, 2019 - cell.com
Cancer metastasis is no longer viewed as a linear cascade of events but rather as a series
of concurrent, partially overlapping processes, as successfully metastasizing cells assume …

[HTML][HTML] Nanocarrier-based drug combination therapy for glioblastoma

M Zhao, D van Straten, MLD Broekman, V Préat… - Theranostics, 2020 - ncbi.nlm.nih.gov
The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …

[HTML][HTML] Perturbation-response genes reveal signaling footprints in cancer gene expression

M Schubert, B Klinger, M Klünemann, A Sieber… - Nature …, 2018 - nature.com
Aberrant cell signaling can cause cancer and other diseases and is a focal point of drug
research. A common approach is to infer signaling activity of pathways from gene …

Constitutive activation of STAT 3 in breast cancer cells: A review

K Banerjee, H Resat - International journal of cancer, 2016 - Wiley Online Library
Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in
numerous cancer types, including more than 40% of breast cancers. In contrast to tight …

Targeting cancer cell dormancy

A Recasens, L Munoz - Trends in pharmacological sciences, 2019 - cell.com
Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed
quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to …